Raymond James Bullish On This Penny Stock's Reprioritized Pipeline

Raymond James upgraded ProQR Therapeutics N.V. PRQR to Outperform based on a high conviction that "RNA editing" emerges as an impactful field of therapeutics in coming years.
Related: This Penny Stock Biotech Offloads Eye Portfolio To Focus On RNA-Editing.
The analyst notes that targets are plentiful, including Alpha-1-antitrypsin deficiency, on which Raymond James based the new model (assume this will be one of five programs partnered with Eli Lilly And Co LLY with peak royalties of $150 million.
During initiating the coverage, the analyst said to own PRQR for RNA editing alone but got blown up after disappointing Phase 3 sepofarsen data.
Related Content: ProQR Shares Crater After Disappointing Sepofarsen Data In Inherited Vision Loss Disorder.
"Now is our opportunity to own and defend that call, which we are doing with conviction," says Raymond James analyst.
The company makes a bet easier with deprioritization of everything else besides axiomer.
Price Action: PRQR shares are up 3.87% at $0.85 during the market session on the last check Friday.

Analyst Calendar